Last reviewed · How we verify
HMPL-760
HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.
HMPL-760 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for Cholangiocarcinoma with FGFR2 fusion or rearrangement, Urothelial carcinoma with FGFR alterations, Other solid tumors with FGFR genetic alterations.
At a glance
| Generic name | HMPL-760 |
|---|---|
| Sponsor | Hutchmed |
| Drug class | FGFR inhibitor |
| Target | FGFR (Fibroblast Growth Factor Receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
HMPL-760 selectively targets FGFR kinases, which are frequently dysregulated in various solid tumors through mutations, amplifications, or translocations. By inhibiting FGFR-mediated signaling pathways, the drug suppresses tumor cell proliferation and survival in FGFR-dependent cancers. This mechanism is particularly relevant in tumors with FGFR alterations where the pathway drives oncogenic growth.
Approved indications
- Cholangiocarcinoma with FGFR2 fusion or rearrangement
- Urothelial carcinoma with FGFR alterations
- Other solid tumors with FGFR genetic alterations
Common side effects
- Hyperphosphatemia
- Diarrhea
- Fatigue
- Nausea
- Stomatitis
Key clinical trials
- A Phase III Study of HMPL-760 in Combination With R-GemOx Versus Placebo in Combination With R-GemOx in Relapsed/Refractory DLBCL (PHASE3)
- Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL (PHASE2)
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (PHASE1)
- HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HMPL-760 CI brief — competitive landscape report
- HMPL-760 updates RSS · CI watch RSS
- Hutchmed portfolio CI